BioWorld MedTech

Sep. 13, 2013

TherOx seeks PMA for SSO2 device for infarct reduction

One small med-tech firm is developing a system that is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients. Read More

Report from Europe: Dfine gets CE mark approval for STAR tumor ablation system

NewCo on the Go: InnerVision develops ultrasound device for the morbidly obese

Washington roundup: MDMA sees traps in MPFS proposal for IDE coverage

Financings roundup: Endo Tools closes second round worth $3.3 million

Agreements/contracts: iCAD aligns with DermEbx for dermatology network

HIT roundup: 3D Systems launches new Bespoke Modeling platform

Med-Tech Briefs

Products Briefs

People in Places

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 8, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Many med-tech company supply chains protected from tariffs

BioWorld MedTech

In the wake of the pandemic, many leading med-tech companies took steps to on-shore and near-shore manufacturing, a move that could protect significant numbers of...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...